Quick Takeaways
- Squadron Capital Management LLC filed SCHEDULE 13G for Pasithea Therapeutics Corp. Common Stock, par value $0.0001 per share (KTTA).
- Disclosed ownership: 9.9%.
- Date of event: 28 Nov 2025.
Squadron Capital Management LLC - 28 Nov 2025 SCHEDULE 13G Report for Pasithea Therapeutics Corp. Common Stock, par value $0.0001 per share (KTTA)
- Filing Manager
- Squadron Capital Management LLC
- Reporting Manager
- Squadron Capital Management LLC
- Symbol
- KTTA
- Shares outstanding
- 22,756,869 shares
- Disclosed Ownership
- 2,252,930 shares
- Ownership
- 9.9%
- Form type
- SCHEDULE 13G
- Filing time
- 05 Dec 2025, 16:10:02 UTC
- Date of event
- 28 Nov 2025
- Next filing
- 17 Feb 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"Squadron Capital Management LLC disclosed 9.9% ownership in Pasithea Therapeutics Corp. Common Stock, par value $0.0001 per share (KTTA) on 28 Nov 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 05 Dec 2025, 16:10.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (4)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Squadron Master Fund LP | 7.3% | 1,649,790 | 0 | 1,649,790 | /s/ Matthew Sesterhenn | Partner, Squadron Partners LLC, its General Partner | |
| Squadron Capital Management LLC | 9.9% | 2,252,930 | 0 | 2,252,930 | /s/ Matthew Sesterhenn | Partner | |
| Matthew Sesterhenn | 9.9% | 2,252,930 | 0 | 2,252,930 | /s/ Matthew Sesterhenn | Matthew Sesterhenn | |
| William Blank | 9.9% | 2,252,930 | 0 | 2,252,930 | /s/ William Blank | William Blank |